Tanshinone IIA inhibits acute promyelocytic leukemia cell proliferation and induces their apoptosis in vivo

被引：46

作者：

Zhang, Kaiji ^{[1
]}

Li, Jian ^{[2
]}

Meng, Wentong ^{[3
]}

Xing, Hongyun ^{[4
]}

Yang, Yiming ^{[2
]}

机构：

[1] Guizhou Med Univ, Affiliated Hosp, Dept Hematol, Guiyang 550004, Guizhou Provinc, Peoples R China

[2] Sichuan Univ, West China Med Sch, Dept Hematol, Chengdu 610041, Sichuan Provinc, Peoples R China

[3] Sichuan Univ, State Key Lab Biotherapy, Lab Stem Cell Biol, Chengdu 610041, Sichuan Provinc, Peoples R China

[4] Sichuan Med Univ, Affiliated Hosp, Dept Hematol, Luzhou 646000, Sichuan Provinc, Peoples R China

来源：

BLOOD CELLS MOLECULES AND DISEASES | 2016年 / 56卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Tanshinone IIA; Acute promyelocytic leukemia; Mice; Apoptosis; Proliferation; TRANS-RETINOIC ACID; MODEL; ATRA; JNK; THERAPY; ALPHA; VITRO;

D O I：

10.1016/j.bcmd.2015.10.007

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Tanshinone LEA (TanIIA) is a traditional Chinese agent and has been widely used for treatment of cardiovascular diseases. Our previous study has shown that TanIIA can induce the differentiation of acute promyelocytic leukemia (APL) cells by increasing C/EBP beta expression and induce APL cell apoptosis in vitro. In this study, we evaluated the activity of TanIIA against APL in vivo. We found that treatment with TanIIA prevented APL-mediated reduction in body weights. Treatment with TanlIA inhibited the proliferation of APL cells and triggered APL cell apoptosis and differentiation in vivo. Treatment with TanIIA significantly prolonged the survival of APL-bearing mice. Our data indicate that TanlIA has potent anti-APL activity with little adverse effect. Crown Copyright (C) 2015 Published by Elsevier Inc. All rights reserved.

引用

页码：46 / 52

页数：7

共 33 条

[1]

Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy [J].

Asou, N ;

Adachi, K ;

Tamura, J ;

Kanamaru, A ;

Kageyama, S ;

Hiraoka, A ;

Omoto, E ;

Akiyama, H ;

Tsubaki, K ;

Saito, K ;

Kuriyama, K ;

Oh, H ;

Kitano, K ;

Miyawaki, S ;

Takeyama, K ;

Yamada, O ;

Nishikawa, K ;

Takahashi, M ;

Matsuda, S ;

Ohtake, S ;

Suzushima, H ;

Emi, N ;

Ohno, R .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :78-85

[2]

AIDA (all-trans retinoic acid plus idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Pilot study [J].

Avvisati, G ;

LoCoco, F ;

Diverio, D ;

Falda, M ;

Ferrara, F ;

Lazzarino, M ;

Russo, D ;

Petti, MC ;

Mandelli, F .

BLOOD, 1996, 88 (04) :1390-1398

[3]

Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia [J].

Ducas, R. A. ;

Seftel, M. D. ;

Ducas, J. ;

Seifer, C. .

JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2011, 41 (02) :117-118

[4]

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia [J].

Fenaux, P ;

Chastang, C ;

Chevret, S ;

Sanz, M ;

Dombret, H ;

Archimbaud, E ;

Fey, M ;

Rayon, C ;

Huguet, F ;

Sotto, JJ ;

Gardin, C ;

Makhoul, PC ;

Travade, P ;

Solary, E ;

Fegueux, N ;

Bordessoule, D ;

San Miguel, J ;

Link, H ;

Desablens, B ;

Stamatoullas, A ;

Deconinck, E ;

Maloisel, F ;

Castaigne, S ;

Preudhomme, C ;

Degos, L .

BLOOD, 1999, 94 (04) :1192-1200

[5]

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4) [J].

Iland, Harry J. ;

Bradstock, Ken ;

Supple, Shane G. ;

Catalano, Alberto ;

Collins, Marnie ;

Hertzberg, Mark ;

Browett, Peter ;

Grigg, Andrew ;

Firkin, Frank ;

Hugman, Amanda ;

Reynolds, John ;

Di Iulio, Juliana ;

Tiley, Campbell ;

Taylor, Kerry ;

Filshie, Robin ;

Seldon, Michael ;

Taper, John ;

Szer, Jeff ;

Moore, John ;

Bashford, John ;

Seymour, John F. .

BLOOD, 2012, 120 (08) :1570-1580

[6]

Tanshinone IIA inhibits LPS-induced NF-κB activation in RAW 264.7 cells:: Possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways [J].

Jang, Seon ;

Kim, Hyung Jin ;

Kim, Young-Jun ;

Jeong, Seung-Il ;

You, Yong-Ouk .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 542 (1-3) :1-7

[7]

Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia [J].

Lallemand-Breitenbach, V ;

Guillemin, MC ;

Janin, A ;

Daniel, MT ;

Degos, L ;

Kogan, SC ;

Bishop, JM ;

de Thé, H .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (07) :1043-1052

[8]

LANOTTE M, 1991, BLOOD, V77, P1080

[9]

Tanshinone IIA Inhibits HIF-1α and VEGF Expression in Breast Cancer Cells via mTOR/p70S6K/RPS6/4E-BP1 Signaling Pathway [J].

Li, Guobing ;

Shan, Changyu ;

Liu, Lei ;

Zhou, Ting ;

Zhou, Jing ;

Hu, Xiaoye ;

Chen, Yibiao ;

Cui, Hongjuan ;

Gao, Ning .

PLOS ONE, 2015, 10 (02)

[10]

Tanshinone IIA in Acute Promyelocytic Leukemia [J].

Li, Jian ;

Zhang, Kaiji ;

Meng, Wentong ;

Yang, Yiming .

AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2012, 344 (04) :283-288

← 1 2 3 4 →